{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuromyelitis+Optica+and+Neuromyelitis+Optica+Spectrum+Disorders&page=2",
    "query": {
      "condition": "Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuromyelitis+Optica+and+Neuromyelitis+Optica+Spectrum+Disorders&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T05:08:31.403Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03942952",
      "title": "PEDIATRIC SONICS: Pediatric Study of Neuropsychology and Imaging in CNS Demyelinating Syndromes.",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis, Relapsing-Remitting",
        "Neuromyelitis Optica",
        "Acute Disseminated Encephalomyelitis",
        "Transverse Myelitis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "12 Years to 21 Years"
      },
      "enrollment_count": 49,
      "start_date": "2019-10-22",
      "completion_date": "2023-06-30",
      "has_results": false,
      "last_update_posted_date": "2023-09-05",
      "last_synced_at": "2026-05-22T05:08:31.403Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03942952"
    },
    {
      "nct_id": "NCT06374264",
      "title": "Acceptability and Safety of MR-C-014 in Persons With Neuromyelitis Optica Spectrum Disorder",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Neuromyelitis Optica Spectrum Disorder"
      ],
      "interventions": [
        {
          "name": "MR-C-014",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "MedRhythms, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 30,
      "start_date": "2024-11-12",
      "completion_date": "2026-03-31",
      "has_results": false,
      "last_update_posted_date": "2025-12-15",
      "last_synced_at": "2026-05-22T05:08:31.403Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia • Boston, Massachusetts",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06374264"
    },
    {
      "nct_id": "NCT02073279",
      "title": "Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neuromyelitis Optica (NMO)",
        "NMO Spectrum Disorder (NMOSD)"
      ],
      "interventions": [
        {
          "name": "Satralizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "18 Years to 74 Years"
      },
      "enrollment_count": 95,
      "start_date": "2014-08-05",
      "completion_date": "2022-01-31",
      "has_results": true,
      "last_update_posted_date": "2023-03-01",
      "last_synced_at": "2026-05-22T05:08:31.403Z",
      "location_count": 20,
      "location_summary": "Aurora, Colorado • Miami, Florida • Vero Beach, Florida + 17 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Vero Beach",
          "state": "Florida"
        },
        {
          "city": "Columbus",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02073279"
    },
    {
      "nct_id": "NCT05840055",
      "title": "ACT with NMOSD Patients and Caregivers Pilot Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "NMO Spectrum Disorder"
      ],
      "interventions": [
        {
          "name": "Acceptance and Commitment Therapy",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2023-08-01",
      "completion_date": "2024-11-21",
      "has_results": false,
      "last_update_posted_date": "2025-01-07",
      "last_synced_at": "2026-05-22T05:08:31.403Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05840055"
    },
    {
      "nct_id": "NCT03011541",
      "title": "Stem Cell Ophthalmology Treatment Study II",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Retinal Disease",
        "Age-Related Macular Degeneration",
        "Retinitis Pigmentosa",
        "Stargardt Disease",
        "Optic Neuropathy",
        "Nonarteritic Ischemic Optic Neuropathy",
        "Optic Atrophy",
        "Optic Nerve Disease",
        "Glaucoma",
        "Leber Hereditary Optic Neuropathy",
        "Blindness",
        "Vision Loss Night",
        "Vision Loss Partial",
        "Vision, Low",
        "Retinopathy",
        "Maculopathy",
        "Macular Degeneration",
        "Retina Atrophy"
      ],
      "interventions": [
        {
          "name": "Arm 1",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "MD Stem Cells",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 500,
      "start_date": "2016-01",
      "completion_date": "2027-07-31",
      "has_results": false,
      "last_update_posted_date": "2025-03-20",
      "last_synced_at": "2026-05-22T05:08:31.403Z",
      "location_count": 2,
      "location_summary": "Westport, Connecticut • Coral Springs, Florida",
      "locations": [
        {
          "city": "Westport",
          "state": "Connecticut"
        },
        {
          "city": "Coral Springs",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03011541"
    },
    {
      "nct_id": "NCT06312644",
      "title": "Study of Ultomiris® (Ravulizumab) Safety in Pregnancy",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Ultomiris-exposed Pregnant/ Postpartum",
        "Pregnancy",
        "Paroxysmal Nocturnal Hemoglobinuria (PNH)",
        "Atypical Hemolytic Uremic Syndrome (aHUS)",
        "Generalized Myasthenia Gravis (gMG)",
        "Neuromyelitis Optica Spectrum Disorder (NMOSD)"
      ],
      "interventions": [
        {
          "name": "Ultomiris",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 75,
      "start_date": "2024-12-16",
      "completion_date": "2034-07-11",
      "has_results": false,
      "last_update_posted_date": "2026-04-16",
      "last_synced_at": "2026-05-22T05:08:31.403Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06312644"
    },
    {
      "nct_id": "NCT05204459",
      "title": "MS-ResearchBiomarkerS",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis",
        "Multiple Sclerosis, Relapsing-Remitting",
        "Multiple Sclerosis, Primary Progressive",
        "Multiple Sclerosis, Secondary Progressive",
        "Clinically Isolated Syndrome",
        "Radiologically Isolated Syndrome",
        "Neuromyelitis Optica Spectrum Disorders",
        "Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease",
        "Neurologic Autoimmune Disease",
        "Neurologic Disorder",
        "Healthy Aging"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Cedars-Sinai Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1000,
      "start_date": "2021-11-11",
      "completion_date": "2041-11-11",
      "has_results": false,
      "last_update_posted_date": "2024-02-06",
      "last_synced_at": "2026-05-22T05:08:31.403Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05204459"
    },
    {
      "nct_id": "NCT02028884",
      "title": "Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neuromyelitis Optica (NMO)",
        "NMO Spectrum Disorder (NMOSD)"
      ],
      "interventions": [
        {
          "name": "Satralizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Baseline Treatment",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "12 Years to 74 Years"
      },
      "enrollment_count": 85,
      "start_date": "2014-02-20",
      "completion_date": "2021-12-23",
      "has_results": true,
      "last_update_posted_date": "2023-04-18",
      "last_synced_at": "2026-05-22T05:08:31.403Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02028884"
    },
    {
      "nct_id": "NCT02276963",
      "title": "Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neuromyelitis Optica",
        "Neuromyelitis Optica Spectrum Disorder"
      ],
      "interventions": [
        {
          "name": "Ublituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 6,
      "start_date": "2016-01",
      "completion_date": "2019-02-15",
      "has_results": true,
      "last_update_posted_date": "2019-06-06",
      "last_synced_at": "2026-05-22T05:08:31.403Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02276963"
    },
    {
      "nct_id": "NCT01892345",
      "title": "A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neuromyelitis Optica",
        "Neuromyelitis Optica Spectrum Disorder"
      ],
      "interventions": [
        {
          "name": "Eculizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 143,
      "start_date": "2014-04-11",
      "completion_date": "2018-07-17",
      "has_results": true,
      "last_update_posted_date": "2019-06-26",
      "last_synced_at": "2026-05-22T05:08:31.403Z",
      "location_count": 19,
      "location_summary": "Scottsdale, Arizona • Carlsbad, California • Washington D.C., District of Columbia + 15 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Carlsbad",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01892345"
    }
  ]
}